Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Hurwitz Website

Arthur Andrew Hurwitz, Ph.D.

Selected Publications

1)  Zhu Z, Singh V, Watkins SK, Bronte V, Shoe JL, Feigenbaum L, Hurwitz AA.
High-avidity T cells are preferentially tolerized in the tumor microenvironment.
Cancer Res. 73: 595-604, 2013.
2)  Watkins SK, Hurwitz AA.
FOXO3: A master switch for regulating tolerance and immunity in dendritic cells.
Oncoimmunology. 1: 252-254, 2012.
3)  Hurwitz AA, Watkins SK.
Immune suppression in the tumor microenvironment: a role for dendritic cell-mediated tolerization of T cells.
Cancer Immunol. Immunother. 61: 289-93, 2012.
4)  Watkins SK, Zhu Z, Watkins KE, Hurwitz AA.
Isolation of immune cells from primary tumors.
J Vis Exp. e3952, 2012.
5)  Hudson RS, Yi M, Esposito D, Watkins SK, Hurwitz AA, Yfantis HG, Lee DH, Borin JF, Naslund MJ, Alexander RB, Dorsey TH, Stephens RM, Croce CM, Ambs S.
MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer.
Nucleic Acids Res. 40: 3689-703, 2012.
6)  Hudson RS, Yi M, Esposito D, Glynn SA, Starks AM, Yang Y, Schetter AJ, Watkins SK, Hurwitz AA, Dorsey TH, Stephens RM, Croce CM, Ambs S.
MicroRNA-106b-25 cluster expression is associated with early disease recurrence and targets caspase-7 and focal adhesion in human prostate cancer.
Oncogene. [Epub ahead of print], 2012.
7)  Watkins SK, Zhu Z, Riboldi E, Shafer-Weaver KA, Stagliano KE, Sklavos MM, Ambs S, Yagita H, Hurwitz AA.
FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer.
J. Clin. Invest. 121: 1361-72, 2011.
8)  Chen X, Hamano R, Subleski JJ, Hurwitz AA, Howard OM, Oppenheim JJ.
Expression of costimulatory TNFR2 induces resistance of CD4(+)FoxP3(-) conventional T cells to suppression by CD4(+)FoxP3(+) regulatory T Cells.
J. Immunol. 185: 174-82, 2010.
9)  Shafer-Weaver KA, Anderson MJ, Stagliano K, Malyguine A, Greenberg NM, Hurwitz AA.
Cutting Edge: Tumor-specific CD8+ T cells infiltrating prostatic tumors are induced to become suppressor cells.
J. Immunol. 183: 4848-52, 2009.
10)  Shafer-Weaver KA, Watkins SK, Anderson MJ, Draper LJ, Malyguine A, Alvord WG, Greenberg NM, Hurwitz AA.
Immunity to murine prostatic tumors: continuous provision of T-cell help prevents CD8 T-cell tolerance and activates tumor-infiltrating dendritic cells.
Cancer Res. 69: 6256-64, 2009.
Click Here to View Expanded Bibliography.

This page was last updated on 4/11/2013.